Mycoplasma bovis, a bovine bacterial pathogen, has been implicated as a cause of contagious mastitis, respiratory tract disease, arthritis, otitis media and interna, and a host of other disease processes in cattle. It was first identified as a contagious bovine mastitis pathogen in 1961,1 and much effort has been made toward establishing proper diagnostic, treatment, prevention, and control measures.
Mycoplasma bovis–associated diseases are costly to beef and dairy production systems worldwide. Cattle producers incur costs to treat infected animals as well as replace those culled from the production facility. Dairy farmers may incur additional costs in the form of decreased premiums or penalties in bulk tank sales.
Like other Mycoplasma spp, M bovis lacks a typical bacterial cell wall.2 Traditional bacteriocidal antimicrobials, such as ceftiofur and penicillin G procaine, which inhibit bacterial cell wall synthesis, have little effect against M bovis. Therefore, when faced with treating an M bovis – associated respiratory tract disease in their cattle, producers may perceive that a treatment failure has occurred if cattle are treated with such antimicrobials without results of bacteriologic culture. Vaccinating dams against respiratory tract pathogens, such as infectious bovine rhinotracheitis virus, parainfluenza 3 virus, bovine respiratory syncytial virus, bovine viral diarrhea virus, Mannhaemia hemolytica, and Pasteurella multocida, prior to calving has resulted in increases in specific IgG concentrations against these pathogens, which are then passively transferred to calves via colostrum.
The purpose of the controlled trial reported here was to determine whether vaccinating cows during late gestation against M bovis would result in adequate concentrations of M bovis–specific IgG1 in serum, colostrum, and milk.
Distilled, deionized water
Sample to positive
Pulmo-Guard MpB, Boehringer Ingelhiem Vetmedica Inc, St Joseph, Mo.
Intercooled Stata for Windows, version 9.0, Stata Corp, College Station, Tex.
Garrity GM, Boone DR, Castenholz RW, eds. Bergey's manual of systematic bacteriology. Vol 1. 2nd ed. New York: Springer-Verlag Inc, 2001.
Ishikawa H. Observation of lymphocyte function in perinatal cows and neonatal calves. Nippon Juigaku Zasshi 1987;49:469–475.
Kashiwazaki Y, Maede Y, Namioka S. Transformation of bovine peripheral blood lymphocytes in the perinatal period. Nippon Juigaku Zasshi 1985;47:337–339.
Kehrli ME Jr, Nonnecke BJ, Roth JA. Alterations in bovine lymphocyte function during the periparturient period. Am J Vet Res 1989;50:215–220.
Mallard BA, Dekkers JC, Ireland MJ, et al. Alteration in immune responsiveness during the peripartum period and its ramification on dairy cow and calf health. J Dairy Sci 1998;81:585–595.
Detilleux JC, Kehrli ME Jr, Stabel JR, et al. Study of immunological dysfunction in periparturient Holstein cattle selected for high and average milk production. Vet Immunol Immunopathol 1995;44:251–267.
Concha C. Cell types and their immunological functions in bovine mammary tissues and secretions—a review of the literature. Nord Vet Med 1986;38:257–272.
Watson DL. Immunological functions of the mammary gland and its secretion—comparative review. Aust J Biol Sci 1980;33:403–422.